Company
United StatesPublic company, NASDAQ: SMMTSummit Therapeutics, Inc. (NASDAQ: SMMT), Palo Alto, CA – FDA Inspections
Inspection records and compliance data for Summit Therapeutics, Inc. in Palo Alto, CA. 1 FDA inspection on record, last inspected April 10, 2026. Publicly traded as NASDAQ: SMMT.
Company Profile
This profile covers Summit Therapeutics, Inc. based in Palo Alto, CA, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected April 10, 2026.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| April 10, 2026 | Not classified | Human Drugs | 1315522 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Summit Therapeutics, Inc.
Stock ticker
SMMT
Exchange
NASDAQ
Share price
$14.40
Market cap
$11.5B
Price as of
November 6, 2026
FEI Number
3042741046
Address
1000 Page Mill Rd, Palo Alto, CA 94304-1019, United States
Country
United States
ID: 6717ca4e-4049-414c-b9af-3028150c88dc